sameAs
Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cellsCandidate gene association studies: a comprehensive guide to useful in silico toolsPhenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironmentType II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymesCharacterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumorsThe expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functionsA comprehensive nomenclature for serine proteases with homology to tissue kallikreinsGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesTTYH2, a human homologue of the Drosophila melanogaster gene tweety, is located on 17q24 and upregulated in renal cell carcinoma3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayerIdentification of seven new prostate cancer susceptibility loci through a genome-wide association studySeven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library.Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load.A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle.Expression of PTRF in PC-3 Cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways.Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.Genetic association of the KLK4 locus with risk of prostate cancer.Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread.Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses.A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate CancerMultiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.Fusion transcript loci share many genomic features with non-fusion loci.The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migrationExploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.Bone and prostate cancer cell interactions in metastatic prostate cancer.Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
P50
Q24306210-6032E868-6562-4B4E-814F-C66545ADB1EFQ26851744-39B46B3D-5373-40FB-8796-8D2318BC1813Q27335274-748F2A4F-DDFA-4416-A18B-6035A9177AA1Q28142811-5813C2EA-9839-4872-81FD-B917E49C0233Q28188563-71AA1768-AEE6-4413-B4C8-B0F09C31C812Q28205501-2D1426E7-E397-45D5-ADC9-3F2A2DE0387DQ28248469-0DB00AF1-7F02-4675-9786-7C1E491BED23Q28388497-84F83B27-D80A-46F6-8DB7-33743FC02BD6Q28512590-5019A782-A37F-4CFE-BDFA-69DD7F7DA498Q28544801-F6691118-5D9B-442C-9FC9-F0543FCC4BE8Q29417022-8FFEEF6B-1439-4BE1-B444-225BD133E679Q29417074-FFB51422-C3D6-47E2-B815-2A0292AD42AEQ29417155-B0CD4851-E003-47A7-90B6-F1C5C621276DQ30642105-F3C6510E-698E-4674-AE91-2B8130180FF6Q33473073-924D8250-9032-43D3-9CA6-AEC9B73E45E5Q33850055-1F8F74E8-B409-41F9-BB01-C600FB439CBAQ33860461-8741B7B5-8BB5-48CB-AC84-146DBDC00E0CQ33946634-FCE4EA13-1684-4A5C-A94A-75C8DF5EF8C9Q34059317-270E4B9A-ECF0-4C90-85AA-18F4DAE7AD85Q34087586-F6570BD4-9330-4D04-BAC8-9696C7A6D376Q34412503-8C65FAAF-0C98-47B1-B2DA-2934115BEC10Q34602948-D48722A9-3A4C-41D5-9468-F8A44299C759Q34798735-4383D673-9C9D-46FB-A547-B9833540F6BFQ34998432-01849481-B835-40C0-8F86-C8215272C397Q35097143-2032A7ED-3A7A-45A0-B82B-93CF01DB05F6Q35195958-DCD3E064-11BE-4DD0-9B4B-265DD3D84C61Q35248192-523E5E3A-6712-48EF-A419-E86267A2DBB9Q35327105-67E5D70D-AE67-4F30-B75F-5B11B7D57ADEQ35646703-EAEA7CD1-E75A-4FA5-992D-58DB3E186736Q35815958-143E42F9-88AA-430C-8CE1-BDFC90B1629AQ35857757-CDCED30E-5C01-4EFA-BA59-A012F3B2284BQ35861497-26D3D01F-2DED-4DCA-A204-5C6CCC908545Q35879981-5F567DBA-C0FB-44CC-95F4-04224CE81865Q35928328-5D048711-579C-4A53-A036-FF57FE8DE064Q36477652-6215D9B0-C16D-4424-B65E-BC8BF005E193Q36519378-451E5191-4645-4934-A510-268C1FC6AE1BQ36519383-4A744613-20F4-4E6A-9212-DF11ECCC8DFBQ36616265-9EAEC320-E661-4A92-A6D9-613204B926F6Q36682278-CFEA267C-7112-4863-892B-5800D6B88522Q36718379-6A9FF619-913A-404B-8DFE-20FBAD254AEA
P50
description
Australian oncologist
@en
aŭstralia onkologo
@eo
oncologe uit Australië
@nl
oncolojiste australian
@lfn
oncóloga australiana
@es
عالمة أورام أسترالية
@ar
name
Judith Clements
@ast
Judith Clements
@ca
Judith Clements
@de
Judith Clements
@en
Judith Clements
@es
Judith Clements
@fr
Judith Clements
@ga
Judith Clements
@gl
Judith Clements
@nl
Judith Clements
@sl
type
label
Judith Clements
@ast
Judith Clements
@ca
Judith Clements
@de
Judith Clements
@en
Judith Clements
@es
Judith Clements
@fr
Judith Clements
@ga
Judith Clements
@gl
Judith Clements
@nl
Judith Clements
@sl
altLabel
Judith A. Clements
@en
Judith Ann Clements
@en
Judith Ann Clements
@fr
prefLabel
Judith Clements
@ast
Judith Clements
@ca
Judith Clements
@de
Judith Clements
@en
Judith Clements
@es
Judith Clements
@fr
Judith Clements
@ga
Judith Clements
@gl
Judith Clements
@nl
Judith Clements
@sl
P1153
7202537971
P1412
P1477
Judith Ann Clements
@en
P166
P1960
4CKEMh4AAAAJ
P21
P27
P31
P496
0000-0001-6026-1964